Voyager Therapeutics (VYGR)

• Market cap: $314M
• 1 day: 1.05%
• 5 days: -8.29%
• 1 month: 7.28%
• 3 months: -8.00%
• 6 months: -26.19%
• Year to date: -36.11%
• 1 year: -27.58%
• 5 years: -58.99%
• 10 years: -67.61%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 162

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

6% more call options, than puts

Call options by funds: $272K | Put options by funds: $256K

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

1% more funds holding

Funds holding: 127 [Q2] → 128 (+1) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 37

6.59% less ownership

Funds ownership: 71.02% [Q2] → 64.44% (-6.59%) [Q3]

33% less capital invested

Capital invested by funds: $306M [Q2] → $206M (-$99.6M) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 109% upside
• Avg. target: $17.75 209% upside
• High target: $30 422% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Samantha Semenkow 20% 1-year accuracy 3 / 15 met price target	109% upside $12	Buy Initiated	2 Dec 2024
Canaccord Genuity Sumant Kulkarni 22% 1-year accuracy 7 / 32 met price target	143% upside $14	Buy Maintained	14 Nov 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target	422% upside $30	Buy Reiterated	14 Nov 2024
Leerink Partners Lili Nsongo 0% 1-year accuracy 0 / 2 met price target	161% upside $15	Outperform Initiated	16 Oct 2024